559 related articles for article (PubMed ID: 26404187)
1. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Fredriksen M; Peleikis DE
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
3. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
4. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
Fredriksen M; Halmøy A; Faraone SV; Haavik J
Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
[TBL] [Abstract][Full Text] [Related]
6. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
7. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
[TBL] [Abstract][Full Text] [Related]
8. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
9. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
[TBL] [Abstract][Full Text] [Related]
10. Treatment of attention-deficit/hyperactivity disorder.
Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
[TBL] [Abstract][Full Text] [Related]
12. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
14. ADHD Medication Trends in Turkey: 2009-2013.
Öner Ö; Yilmaz EŞ; Karadağ H; Vural M; Vural EH; Akbulat A; Gürsöz H; Türkçapar H; Kerman S
J Atten Disord; 2017 Dec; 21(14):1192-1197. PubMed ID: 24554298
[TBL] [Abstract][Full Text] [Related]
15. Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study.
Wehmeier PM; Dittmann RW; Banaschewski T
Atten Defic Hyperact Disord; 2015 Jun; 7(2):165-74. PubMed ID: 25416667
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
Slatkoff J; Greenfield B
Expert Opin Investig Drugs; 2006 Jun; 15(6):649-67. PubMed ID: 16732717
[TBL] [Abstract][Full Text] [Related]
17. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.
Stuhec M; Locatelli I
Int J Clin Pharm; 2018 Apr; 40(2):341-344. PubMed ID: 29468526
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Shih HH; Pan YL; Lin HY; Gau SS
J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):148-158. PubMed ID: 31794244
[No Abstract] [Full Text] [Related]
19. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Jain R; Katic A
Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
[TBL] [Abstract][Full Text] [Related]
20. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
